SCHEMBL4548370

SCHEMBL4548370

COc1ccc2cc(/C=C/C(=O)OC(C)(C)C)ccc2c1

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 1/20 0.59
MAOB P27338 1/20 0.54
MEN1 O00255 1/20 0.54
MAPT P10636 1/20 0.54
KMT2A Q03164 1/20 0.54
CA12 O43570 2/20 0.49
CA9 Q16790 2/20 0.49
CA1 P00915 1/20 0.49
F3 P13726 1/20 0.49
CYP3A4 P08684 3/20 0.48
THRB P10828 1/20 0.47
ATM Q13315 1/20 0.47
PDE4A P27815 1/20 0.47
PDE4B Q07343 1/20 0.47
PDE4C Q08493 1/20 0.47
PDE4D Q08499 1/20 0.47
ABCG2 Q9UNQ0 3/20 0.47
GSK3B P49841 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1399888 1.00 ESR1 (0.59) ESR1MAOBMEN1MAPTKMT2A
SCHEMBL4060081 0.92 ESR1 (0.49) ESR1MAOBMEN1MAPTKMT2A
SCHEMBL4060087 0.92 ESR1 (0.49) ESR1MAOBMEN1MAPTKMT2A
SCHEMBL2561341 0.88 F3 (0.64) ESR1MAOBMEN1MAPTKMT2A
SCHEMBL2561337 0.88 F3 (0.64) ESR1MAOBMEN1MAPTKMT2A
SCHEMBL5396218 0.87 PPARA (0.51) MEN1MAPTKMT2ACYP3A4
SCHEMBL5396213 0.87 PPARA (0.51) MEN1MAPTKMT2ACYP3A4
SCHEMBL4054092 0.86 ELANE (0.48) ESR1MAOBMEN1MAPTKMT2A
SCHEMBL13845255 0.86 ELANE (0.48) ESR1MAOBMEN1MAPTKMT2A
SCHEMBL4054087 0.86 ELANE (0.48) ESR1MAOBMEN1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120178750-A1 Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment MERCK SHARP & DOHME CORP. (US) 2012-07-12 US disclosed
US-8168649-B2 Niacin receptor agonists, compositions containing such compounds and methods of treatment Merk Sharp & Dohme Corp. (US) 2012-05-01 US disclosed
US-8168649-B2 Niacin receptor agonists, compositions containing such compounds and methods of treatment Merk Sharp & Dohme Corp. (US) 2012-05-01 US disclosed
US-20100144778-A1 Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment MERCK SHARP & DOHME LLC 2010-06-10 US disclosed
US-20100144778-A1 Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment MERCK SHARP & DOHME LLC 2010-06-10 US disclosed
WO-2007002557-A1 NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT MERCK & CO., INC. (US) 2007-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144778-A1 Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment HCAR1, HCAR2, GPR119 ESR1 1026/4885MAOB 467/4885MEN1 1955/4885
US-20120178750-A1 Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment HCAR1, HCAR2, FFAR1 ESR1 1001/4885MAOB 505/4885MEN1 2028/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.